[HTML][HTML] Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: US Myeloma …
H Hashmi, DK Hansen, LC Peres, OC Puglianini… - …, 2024 - ncbi.nlm.nih.gov
While response rates and survival outcomes have been very promising for idecabtagene
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: US Myeloma …
H Hashmi, DK Hansen, LC Peres… - …, 2024 - pubmed.ncbi.nlm.nih.gov
While response rates and survival outcomes have been very promising for idecabtagene
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: US Myeloma …
H Hashmi, DK Hansen, LC Peres, OC Puglianini… - …, 2024 - europepmc.org
While response rates and survival outcomes have been very promising for idecabtagene
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: US Myeloma …
H Hashmi, DK Hansen, LC Peres, OC Puglianini… - …, 2020 - haematologica.org
While response rates and survival outcomes have been very promising for idecabtagene
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: US Myeloma …
H Hashmi, DK Hansen, LC Peres… - …, 2024 - utsouthwestern.elsevierpure.com
While response rates and survival outcomes have been very promising for idecabtagene
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: US Myeloma …
H Hashmi, DK Hansen, LC Peres, OC Puglianini… - …, 2023 - europepmc.org
While response rates and survival outcomes have been very promising for idecabtagene
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: US Myeloma …
H Hashmi, DK Hansen, LC Peres, OC Puglianini… - …, 2020 - haematologica.org
While response rates and survival outcomes have been very promising for idecabtagene
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …